IRINOTECAN KABI 40 mg/2 mL Koncentrat za otopinu za infuziju Bosnien och Hercegovina - kroatiska - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

irinotecan kabi 40 mg/2 ml koncentrat za otopinu za infuziju

amicus pharma d.o.o. - irinotekan - koncentrat za otopinu za infuziju - 40 mg/2 ml - 1 ml koncentrata za otopinu za infuziju sadrži: 20 mg irinotekanhidrohlorid, trihidrata (što odgovara 17,33 mg/ml irinotekana).

IRINOTECAN KABI 100 mg/5 mL Koncentrat za otopinu za infuziju Bosnien och Hercegovina - kroatiska - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

irinotecan kabi 100 mg/5 ml koncentrat za otopinu za infuziju

amicus pharma d.o.o. - irinotekan - koncentrat za otopinu za infuziju - 100 mg/5 ml - 1 ml koncentrata za otopinu za infuziju sadrži: 20 mg irinotekanhidrohlorid, trihidrata (što odgovara 17,33 mg/ml irinotekana).

Stimufend Europeiska unionen - kroatiska - EMA (European Medicines Agency)

stimufend

fresenius kabi deutschland gmbh - pegfilgrastim - neutropenija - Иммуностимуляторы, , колониестимулирующие faktori - smanjenje duljine trajanja neutropenije i incidencije febrilne neutropenije u odraslih bolesnika liječenih citotoksičnom kemoterapijom zbog zloćudne bolesti (uz iznimku kronične mijeloične leukemije i mijelodisplastičnog sindroma).

Tyenne Europeiska unionen - kroatiska - EMA (European Medicines Agency)

tyenne

fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - imunosupresivi - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

Busulfan Fresenius Kabi Europeiska unionen - kroatiska - EMA (European Medicines Agency)

busulfan fresenius kabi

fresenius kabi deutschland gmbh - busulfan - transplantacija hematopoetskih matičnih stanica - alkilsulfonati - busulfan fresenius kabi slijedi ciklofosfamid (bucy2) je indiciran kao uređaj tretman prije konvencionalne matičnih hematopoetskih stanica (hpct) u odraslih bolesnika kada kombinacija se smatra najbolje dostupne opcije. Бусульфан Фрезениус Каби zatim ciklofosfamid (bucy4) ili мелфалан (bumel) prikazan je kao tretman klima pred konvencionalnim гемопоэтических прогениторных stanica za transplantaciju mali pacijenti.

Glukoza Fresenius Kabi 5% otopina za infuziju Kroatien - kroatiska - HALMED (Agencija za lijekove i medicinske proizvode)

glukoza fresenius kabi 5% otopina za infuziju

fresenius kabi d.o.o., radnička cesta 37a, zagreb, hrvatska - glukoza hidrat - otopina za infuziju - 50 g/1000 ml - urbroj: 1 ml otopine za infuziju sadrži 50,0 mg glukoze, bezvodne (u obliku 55,0 mg glukoza hidrata) 1000 ml otopine za infuziju sadrži 50,0 g glukoze, bezvodne (u obliku 55,0 g glukoza hidrata)

Natrijev klorid Fresenius Kabi 9 mg/ml otopina za infuziju Kroatien - kroatiska - HALMED (Agencija za lijekove i medicinske proizvode)

natrijev klorid fresenius kabi 9 mg/ml otopina za infuziju

fresenius kabi d.o.o., radnička cesta 37a, zagreb, hrvatska - natrijev klorid - otopina za infuziju - 9 mg/ml - urbroj: 1 ml otopine sadrži 9 miligrama natrijevog klorida

Glukoza Fresenius Kabi 10% otopina za infuziju Kroatien - kroatiska - HALMED (Agencija za lijekove i medicinske proizvode)

glukoza fresenius kabi 10% otopina za infuziju

fresenius kabi d.o.o., radnička cesta 37a, zagreb, hrvatska - glukoza hidrat - otopina za infuziju - 100 g/1000 ml - urbroj: 1 ml otopine za infuziju sadrži 100,0 mg glukoze, bezvodne (u obliku 110,0 mg glukoza hidrata). 1000 ml otopine za infuziju sadrži 100,0 g glukoze, bezvodne (u obliku 110,0 g glukoza hidrata).